|
Number of patients (N = 44)
|
28
|
16
|
|
Total number of procedures (N = 150)
|
82
|
68
|
|
Completed procedures
|
78 (95.1%)
|
62 (91.2%)
|
|
Completed PIPACs per patient
|
3 (1–4), range 0–9
|
3.5 (1–6.75), range 0–10
|
|
7–10 procedures
|
1 (3.6%)
|
4 (25.0%)
|
|
4–6 procedures
|
9 (32.1%)
|
4 (25.0%)
|
|
2 or 3 procedures
|
7 (25.0%)
|
3 (18.8%)
|
|
1 procedure
|
10 (35.7%)
|
2 (12.5%)
|
|
0 procedures
|
1 (3.6%)
|
3 (18.8%)
|
|
Primary non-access
|
1 (1.3%)
|
3 (4.8%)
|
|
Secondary non-access
|
1 (1.3%)
|
2 (3.2%)
|
|
RECIST
|
|
Complete remission
|
3 (10.7%)
|
–
|
|
Partial remission
|
9 (32.1%)
|
4 (25.0%)
|
|
Stable disease
|
3 (10.7%)
|
2 (12.5%)
|
|
Disease progression
|
–
|
1 (6.3%)
|
|
Not determined / too few PIPACs
|
13 (46.4%)
|
9 (56.3%)
|
|
Overall peri−/postoperative morbidity
|
1 (0–2), range 0–4
|
1 (0–2), range 0–4
|
|
Total number of adverse events
|
83
|
68
|
|
Procedures without complications
|
34 (40.9%)
|
28 (41.2%)
|
|
CTCAE grade 1
|
21 (25.3%)
|
21 (30.9%)
|
|
CTCAE grade 2
|
19 (22.9%)
|
16 (23.5%)
|
|
CTCAE grade 3
|
7 (8.4%)
|
3 (4.4%)
|
|
CTCAE grade 4
|
2 (2.4%)
|
–
|
|
Overall peri−/postoperative mortality
|
0
|
0
|
